Thus, R-MAM holds potential as an adjuvant therapy alongside established IBD treatments, such as anti-TNF agents or immunosuppressants, potentially enhancing their efficacy while mitigating adverse effects. This evidence concerns the gene TNF and inflammatory bowel disease.